Loading...

I Henderson, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address400 Parnassus Avenue
San Francisco CA 94117
Phone415-353-7070
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. With Decades of Perspective, Craig Henderson Observes That Treatment of Breast Cancer Has Come a Long Way. Oncology (Williston Park). 2017 05 15; 31(5):346-8. Henderson IC. PMID: 28516433.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Targeted therapy: a sea change in the treatment of cancer. Oncology (Williston Park). 2012 Nov; 26(11):1035, 1039. Henderson IC. PMID: 23330342.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res. 2011 Aug 01; 17(15):5170-8. Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF. PMID: 21693655.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    4. Can we abandon anthracyclines for early breast cancer patients? Oncology (Williston Park). 2011 Feb; 25(2):115-24, 127. Henderson IC. PMID: 21456382.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    5. Adjuvant chemotherapy is not for everyone. Breast Cancer Res Treat. 2010 Aug; 123(1):159-62. Henderson IC. PMID: 20549338.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19; 374(9707):2055-2063. Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK. PMID: 20004966.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    7. Impact of high-dose chemotherapy on the ability to deliver subsequent local-regional radiotherapy for breast cancer: analysis of Cancer and Leukemia Group B Protocol 9082. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1305-13. Marks LB, Cirrincione C, Fitzgerald TJ, Laurie F, Glicksman AS, Vredenburgh J, Prosnitz LR, Shpall EJ, Crump M, Richardson PG, Schuster MW, Ma J, Peterson BL, Norton L, Seagren S, Henderson IC, Hurd DD, Peters WP. PMID: 19747781.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    8. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. J Clin Oncol. 2008 May 10; 26(14):2364-72. DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD. PMID: 18390970.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    9. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Med Care. 2008 Mar; 46(3):303-8. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA. PMID: 18388845.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    10. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. 2008 May; 34(3):223-30. Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA. PMID: 18234424.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    11. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct 11; 357(15):1496-506. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. PMID: 17928597.
      View in: PubMed   Mentions: 174     Fields:    Translation:Humans
    12. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007 Aug 20; 25(24):3699-704. Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, Norton L, Winer EP, Hudis CA. PMID: 17704418.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    13. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther. 2007 Jul; 7(7):919-43. Henderson IC, Bhatia V. PMID: 17627452.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    14. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst. 2006 Sep 20; 98(18):1335-8. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Earle CC, Schilsky RL, Christakis NA. PMID: 16985253.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    15. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006 Apr 12; 295(14):1658-67. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. PMID: 16609087.
      View in: PubMed   Mentions: 189     Fields:    Translation:Humans
    16. Axillary surgery: clinical judgment required. J Clin Oncol. 2006 Jan 20; 24(3):325-6. Henderson IC. PMID: 16344313.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    17. Overdiagnosis and overtreatment of breast cancer: rates of ductal carcinoma in situ: a US perspective. Breast Cancer Res. 2005; 7(6):271-5. Kumar AS, Bhatia V, Henderson IC. PMID: 16457703.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    18. The evolving role of aromatase inhibitors in adjuvant breast cancer therapy. Clin Breast Cancer. 2005 Aug; 6(3):206-15. Henderson IC, Piccart-Gebhart MJ. PMID: 16137430.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    19. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005 Jul 20; 97(14):1080-3. Lamont EB, Herndon JE, Weeks JC, Henderson IC, Lilenbaum R, Schilsky RL, Christakis NA. PMID: 16030306.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    20. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol. 2005 Jul 01; 23(19):4287-97. Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF. PMID: 15994142.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    21. Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. Clin Breast Cancer. 2005 Jun; 6(2):150-7. Overmoyer B, Silverman P, Holder LW, Tripathy D, Henderson IC. PMID: 16001993.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    22. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol. 2005 Mar 20; 23(9):1934-40. Bellon JR, Come SE, Gelman RS, Henderson IC, Shulman LN, Silver BJ, Harris JR, Recht A. PMID: 15774786.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    23. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005 Mar 02; 293(9):1073-81. Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L. PMID: 15741529.
      View in: PubMed   Mentions: 92     Fields:    Translation:Humans
    24. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol. 2004 Dec; 31(6 Suppl 13):106-46. Robert NJ, Vogel CL, Henderson IC, Sparano JA, Moore MR, Silverman P, Overmoyer BA, Shapiro CL, Park JW, Colbern GT, Winer EP, Gabizon AA. PMID: 15717740.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    25. Aromatase inhibitors in the management of early breast cancer: optimizing the clinical benefit. Semin Oncol. 2004 Dec; 31(6 Suppl 12):31-4. Henderson IC. PMID: 15719599.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. J Clin Oncol. 2005 Jan 01; 23(1):30-40. Sartor CI, Peterson BL, Woolf S, Fitzgerald TJ, Laurie F, Turrisi AJ, Bogart J, Henderson IC, Norton L. PMID: 15545661.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    27. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol. 2004 Oct 01; 22(19):3893-901. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C. PMID: 15459210.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    28. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004 Sep 02; 351(10):971-7. Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L. PMID: 15342805.
      View in: PubMed   Mentions: 145     Fields:    Translation:HumansCTClinical Trials
    29. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004 Jun 01; 22(11):2061-8. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. PMID: 15169793.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    30. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. J Clin Oncol. 2003 May 01; 21(9):1825-35. Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, Falkson G, Cirrincione CT, Robbins A, Bothun S, Henderson IC, Norton L. PMID: 12721260.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    31. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. PMID: 12637460.
      View in: PubMed   Mentions: 260     Fields:    Translation:HumansCTClinical Trials
    32. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole. Breast Cancer Res Treat. 2003; 80 Suppl 1:S19-26; discussion S27-8. Carlson RW, Henderson IC. PMID: 14535531.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    33. A rose is no longer a rose. J Clin Oncol. 2002 Aug 15; 20(16):3365-8. Henderson IC. PMID: 12177095.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869. J Clin Oncol. 2002 Feb 01; 20(3):732-42. Guidi AJ, Berry DA, Broadwater G, Helmchen B, Bleiweiss IJ, Budman DR, Henderson IC, Norton L, Hayes DF. PMID: 11821455.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    35. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2002 Feb 01; 20(3):743-50. Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J, Costanza M, Freytes CO, Stadtmauer E, Gale RP, Henderson IC, Lazarus HM, McCarthy PL, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, Horowitz MM. PMID: 11821456.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    36. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):261-88. Henderson IC, Patek AJ. PMID: 10066087.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    37. Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541. Cancer J Sci Am. 1997 Mar-Apr; 3(2):107-12. Roach M, Cirrincione C, Budman D, Hayes D, Berry D, Younger J, Hart R, Henderson IC. PMID: 9099461.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    38. New treatments for breast cancer. Semin Oncol. 1996 Aug; 23(4):506-28. Smith G, Henderson IC. PMID: 8757276.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    39. Using clinical trial information in the practice of medicine. Cancer J Sci Am. 1995 Jul-Aug; 1(2):101-3. Henderson IC. PMID: 9166459.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    40. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out. Important Adv Oncol. 1995; 201-14. Smith GA, Henderson IC. PMID: 7672807.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Adjuvant systemic therapy for early breast cancer. Cancer. 1994 Jul 01; 74(1 Suppl):401-9. Henderson IC. PMID: 8004613.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    42. Management of metastatic breast cancer. World J Surg. 1994 Jan-Feb; 18(1):98-111. Wong K, Henderson IC. PMID: 7910993.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    43. Molecular cytogenetics of human breast cancer. Cold Spring Harb Symp Quant Biol. 1994; 59:645-52. Gray JW, Collins C, Henderson IC, Isola J, Kallioniemi A, Kallioniemi OP, Nakamura H, Pinkel D, Stokke T, Tanner M. PMID: 7587125.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    44. Risk factors for breast cancer development. Cancer. 1993 Mar 15; 71(6 Suppl):2127-40. Henderson IC. PMID: 8443762.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    45. Adjuvant systemic therapy: overview. Recent Results Cancer Res. 1993; 127:197-200. Henderson IC. PMID: 8502816.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    46. Systemic adjuvant therapy for breast cancer. Curr Opin Oncol. 1992 Dec; 4(6):1041-9. Tripathy D, Henderson IC. PMID: 1457518.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    47. Biologic variations of tumors. Cancer. 1992 Apr 01; 69(7 Suppl):1888-95. Henderson IC. PMID: 1544087.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans